Chain of custody, and where it begins
Chain of custody, in a regulated setting, begins at sampling. Here it begins when the package arrives.
Purity
Page 8 of 51 of this archive, newest first.
Medutest result on a Wuhan dulaglutide lot lands 0.7 points above the supplier’s stated figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
What changed at FGP in February, and what the company says prompted it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
How a claim degrades between the bench and the listing
A badge asserts that something was tested. It does not assert what, when, on whose sample, by what method, or whether the lot on sale is the lot that was tested.
WWB names the synthesis and fill sites behind its catalogue
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Janoshik, Medutest, PeptideMeter, VendorInvestigate: a capability audit
The absence of microbiological capability in this market is a commercial fact with a straightforward explanation, and it is worth understanding before blaming anybody for it.
GGPeps names the synthesis and fill sites behind its catalogue
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
Counter-ion, water, salt: three masses with no chromatogram
Aggregates dissociate in the mobile phase and are recorded as monomer. Only a size-based separation reports them.
Low endotoxin recovery: the interference nobody looks for
We submitted vials for endotoxin determination and report the results, the method and the laboratory, because a pyrogen figure without a method is as empty as a purity…
Quadrupole, time-of-flight, orbital trap: what each class can and cannot see
Calibration drift is real, unremarkable, and the reason serious laboratories run internal standards.
Independent analysis puts a SWB tirzepatide lot at 98.3%, against 95.6% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
CPC names the synthesis and fill sites behind its catalogue
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
PeptideMeter result on a Tianjin liraglutide lot lands 4.0 points above the supplier’s stated figure
A reminder that a purity figure is the output of a method, and that methods differ.
Singapore health authority warns on falsified liraglutide pens
Reported from the analysis, not from a warning notice.
An interlaboratory comparison nobody had run
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The badge is about a sample. The listing is about a product.
A badge asserts that something was tested. It does not assert what, when, on whose sample, by what method, or whether the lot on sale is the lot that was tested.
Independent analysis puts a SGN dulaglutide lot at 96.0%, against 93.3% on the certificate
The supplier confirmed the determination and supplied the method behind its own figure inside a week.
The sample is not the batch
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.